In an effort to reduce the recurrence rate and slow the growth of remnant desmoid disease, our team has recently been placing our FAP patients specifically on sirolimus (rapamycin) which is a mammalian target of rapamycin inhibitor (mTOR). Here, MTOR is linked to Familial adenomatous polyposis.